In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

One of Jupiter’s biggest moons has the potential to harbour life in a subsurface sea. The nature of its core will provide information about that ocean.

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

With 97,000 members worldwide, the ICE exists to improve lives by ensuring the world has the engineering capacity and infrastructure systems it needs to enable our planet and our people to thrive.

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

The Aalto Science Institute (AScI) International Summer Research Programme seeks 50+ talented research-driven students to join cutting-edge projects, collaborate with top research groups at Aalto ...

With its Q4 2024 financials on Friday, Novartis (NYSE:NVS) (OTCPK:NVSEF) indicated a delayed timeline for initial data from a Phase 3 trial for a cardiac therapy it co-develops with Ionis ...

TD Cowen analyst Steve Scala reiterated a Hold rating on Novartis (NVS – Research Report) today and set a price target of $125.00. The company’s shares opened today at $106.18. According to ...

(Bloomberg) — Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit will likely grow by a high ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...